<DOC>
	<DOCNO>NCT00031655</DOCNO>
	<brief_summary>The reason study determine whether new method blood stem cell transplant ( also know bone marrow transplant ) able treat acute lymphocytic leukemia . Blood stem cell `` seed cell '' necessary make blood cell . This new method transplant use combination low dose radiation chemotherapy may less toxic cause less harm conventional transplant . This low dose transplant call `` nonmyeloablative transplant '' . Researchers want see use less radiation less chemotherapy combine new immune suppress drug transplant help stem cell transplant work . Researchers hope treatment cure acute lymphocytic leukemia few side effect . Researchers hop see mixture recipient donor blood cell transplant . This mixture donor recipient blood cell call `` mixed chimerism '' . Researchers hope donor cell attack eliminate leukemia . This call `` graft-versus-leukemia '' effect . In addition , transplant , white blood cell donor may give enhance `` boost '' graft-versus-leukemia effect , hopefully remove remain cancer cell . This study do present time blood stem cell transplantation ( bone marrow transplantation ) know curative therapy acute lymphocytic leukemia . Because age underlie health status acute lymphocytic leukemia patient higher likelihood experience severe harm conventional blood stem cell transplant . Researchers study see new nonmyeloablative method low dose radiation low dose chemotherapy give transplant immune suppressive drug transplant help make transplant safer also cure acute lymphocytic leukemia</brief_summary>
	<brief_title>Reduced Intensity Donor Stem Cell Transplant Treating Patients With High Risk Acute Lymphocytic Leukemia Complete Remission</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine one-year disease-free survival ( DFS ) &gt; 25 % achieve among adult patient high risk acute lymphocytic leukemia ( ALL ) complete remission ( CR ) undergo nonmyeloablative allografting . II . To determine one-year DFS &gt; = 40 % achieve among pediatric patient high risk ALL CR undergo nonmyeloablative allografting . SECONDARY OBJECTIVES : I . To determine day +200 transplant-related mortality ( TRM ) &lt; 25 % achieve among patient high risk ALL CR undergo nonmyeloablative allografting . II . To evaluate efficacy toxicity donor lymphocyte infusion ( DLI ) treatment minimal residue disease ( MRD ) nonmyeloablative allografting patient high risk ALL CR . OUTLINE : NONMYELOALATIVE CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) day -4 -2 undergo total body irradiation ( TBI ) day 0 . TRANSPLANTATION : Patients undergo allogeneic peripheral blood stem cell transplantation ( PBSCT ) day 0 . Patients minimal residual disease may receive donor lymphocyte infusion IV . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) every 12 hour day -3 100 taper day 177 mycophenolate mofetil PO 8 hour day 0 40 taper day 96 . After completion study treatment , patient follow day 28 , 56 , 84 , 120 , 180 , 360 ; 18 month ; annually 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>ADULT PATIENTS : Patients 5075 year old high risk ALL first CR ( CR1 ) ALL CR &gt; = second CR ( CR2 ) Patients &gt; = 18 year old &lt; 50 year old high risk ALL CR1 eligible conventional allogeneic transplantation base general medical condition Patients &gt; = 18 year old &lt; 50 year old high risk ALL CR1 refuse conventional allogeneic transplant Patients &gt; = 18 year old &lt; 50 year old ALL CR &gt; = CR2 eligible conventional allogeneic transplantation base general medical condition Patients &gt; = 18 year old &lt; 50 year old high risk ALL CR &gt; = CR2 refuse conventional allogeneic transplant CR define &lt; 5 % blast morphology bone marrow aspirate absence peripheral blast High risk adult ALL CR1 include patient one follow : Age &gt; =30 year Non Tcell phenotype Cytogenetic abnormality include ( 9 ; 22 ) , ( 4 ; 11 ) , trisomy 8 , monosomy 7 Failure achieve CR 4 week induction chemotherapy PEDIATRIC PATIENTS : Patients &lt; 18 year old ALL high risk CR1 candidate conventional allogeneic transplantation base general medical condition Patients &lt; 18 year old ALL CR &gt; = CR2 candidate conventional allogeneic transplantation base general medical condition Patients &lt; 12 year old require approval Fred Hutchinson Cancer Research Center ( FHCRC ) principal investigator prior enrollment CR define &lt; 5 % blast morphology bone marrow aspirate absence peripheral blast High risk pediatric ALL CR1 include patient one follow : Cytogenetic abnormality include : ( 9 ; 22 ) white blood cell ( WBC ) &gt; = 25,000 diagnosis ( 4 ; 11 ) patient &lt; 1 year old &gt; = 10 year old Hypodiploidy ( &lt; 45 chromosome ) Failure achieve CR 4 week induction chemotherapy Persistent peripheral blast one week induction chemotherapy DONOR : FHCRC match Grade 2.1 : Unrelated donor prospectively : Matched human leukocyte antigen ( HLA ) DRB1 DQB1 allele ( must define high resolution type ) Only single allele disparity allow HLAA , B , C define high resolution type DONOR : A positive antidonor cytotoxic crossmatch absolute donor exclusion ; donor exclude preexist immunoreactivity identify would jeopardize donor hematopoietic cell engraftment ; determination base standard practice individual institution ; recommended procedure patient 10 10 HLA allele level ( phenotypic ) match obtain panel reactive antibody ( PRA ) screen class I class II antigens patient hematopoietic cell transplantation ( HCT ) ; PRA show &gt; 10 % activity , flow cytometric B T cell cytotoxic cross match obtain ; donor exclude cytotoxic cross match assay positive ; patient HLA class I allele mismatch , flow cytometric B T cell cytotoxic cross match obtain regardless PRA result DONOR : Patient donor pair homozygous mismatch allele consider twoallele mismatch , i.e. , patient A*0101 donor A*0102 , type mismatch allow DONOR : Donor must consent peripheral blood stem cell ( PBSC ) mobilization filgrastim ( GCSF ) arrange National Marrow Donor Program ( NMDP ) donor center Active central nervous system ( CNS ) disease Presence circulate leukemic blast ( peripheral blood ) detect standard pathology Fertile men woman unwilling use contraceptive technique 12 month follow treatment Pregnancy breastfeed Human immunodeficiency virus ( HIV ) seropositivity ORGAN DYSFUNCTION , ADULT CRITERIA : Requiring supplementary continuous oxygen OR diffusing capacity lung carbon monoxide ( DLCO ) &lt; 40 % Cardiac ejection fraction &lt; 35 % Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bridge fibrosis , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Karnofsky performance score &lt; 50 ORGAN DYSFUNCTION , PEDIATRIC CRITERIA : Lansky playperformance score &lt; 40 Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>